Oren Gilad, Ph.D., is the president and CEO of Atrin Pharmaceuticals. He received his BA in Animal Science from the Hebrew University in Israel and his Ph.D. in Pathology from the University of California at Davis.
Oren is a dynamic scientific-entrepreneur and business leader who has built and profitably sold two small businesses. He is an innovator, strategic thinker, planner, and problem solver. He has leadership skills, proven execution skills, and extensive hands-on experience across the different phases of drug research and development and leadership. He has authored several high-impact scientific articles, the most recent demonstrating the importance of the ATR pathway in cancer development and prevention.
Oren's extensive cancer research over the last several years has furthered his desire to develop a company that will be able to take these new concepts and bring new successful therapies to help cancer patients of the world. Oren is a member of the Biotechnology Advisory Committee at Bucks County Community College and of the Entrepreneur Council Executive Committee of the Pennsylvania Biotechnology Center. He was recently named 2015 EY Entrepreneur Of The Year Greater Philadelphia Finalist in the Life Science category.